Tage Honoré
Net worth: 572 030 $ as of 29/06/2026
Net worth: 572 030 $ as of 29/06/2026
Dr. Tage Honoré is an Independent Director at Vanda Pharmaceuticals, Inc., a Head-Pharmaceutical Development at Avicenna Biosciences, Inc. and a President at Aestus Partners LLC.
He is on the Board of Directors at Vanda Pharmaceuticals, Inc. Dr. Honoré was previously employed as a Chairman by Dep-Xplora ApS.
He received his graduate degree from the University of Copenhagen and a doctorate degree from the University of Copenhagen.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 03/06/2026 | 93,469 ( 0.16% ) | 572 030 $ | 29/06/2026 |
| Companies | Position | Start |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Director/Board Member | 14/03/2023 |
Avicenna Biosciences, Inc.
Avicenna Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that intends to redesign and optimize drug candidates | Corporate Officer/Principal | 31/12/2019 |
| Companies | Position | End |
|---|---|---|
Dep-Xplora ApS
Dep-Xplora ApS BiotechnologyHealth Technology Develops non-steroidal anti-inflammatory drugs for arthritis pain | Chairman | 28/02/2019 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company, which focuses on the development and commercialization of therapies | Health Technology |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dep-Xplora ApS
Dep-Xplora ApS BiotechnologyHealth Technology Develops non-steroidal anti-inflammatory drugs for arthritis pain | Health Technology |
Avicenna Biosciences, Inc.
Avicenna Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that intends to redesign and optimize drug candidates | Health Technology |
Select your edition
All financial news and data tailored to specific country editions